| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Treatment with albiflorin (50-200 μM; 3 hours pretreatment; PC12 cells) can greatly ameliorate the reduction in cell viability caused by glutamate (Glu) [1]. Reactive oxygen species accumulation, B-cell lymphoma 2 (Bcl-2)/Bax ratio reduction, and Glu-induced nuclear and mitochondrial apoptotic alterations were all markedly alleviated by albiflorin (100 μM; 3 hours pretreatment; PC12 cells) treatment[1]. The treatment of PC12 cells with 100 μM albiflorin three hours prior to treatment increases the phosphorylation of AKT and its downstream component GSK-3β [1].
|
|---|---|
| ln Vivo |
Albiflorin (50 mg/kg; i.p.; once daily; for 15 days; Wistar rats) therapy significantly enhanced the paw withdrawal threshold (PWT) on postoperative days 11 and 15 in rats. Albiflorin suppresses the activation of the p38 MAPK pathway in spinal microglia and therefore upregulates IL-1β and TNF-α. Albiflorin has strong effects in decreasing astrocyte activation, preventing the phosphorylation and overexpression of c-JNK (p-JNK) in astrocytes, and reducing the concentration of the chemokine CXCL1 in the spinal cord [2].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: PC12 Cell Tested Concentrations: 50 μM, 100 μM, 200 μM Incubation Duration: 3 hrs (hours) of pretreatment Experimental Results: Dramatically improved Glu-induced decrease in cell viability. Apoptosis analysis [1] Cell Types: PC12 Cell Tested Concentrations: 100 μM Incubation Duration: 3 hrs (hours) of pretreatment Experimental Results: Significant improvement in the reduction of Glu-induced apoptotic changes in the nucleus and mitochondria. Western Blot Analysis[1] Cell Types: PC12 Cell Tested Concentrations: 100 μM Incubation Duration: 3 hrs (hours) of pretreatment Experimental Results: Enhanced phosphorylation of AKT and its downstream component GSK-3β. |
| Animal Protocol |
Animal/Disease Models: Wistar rats (7 weeks old; 200-220 g), suffering from chronic constrictive injury (CCI) [2]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; intraperitoneal (ip) injection. one time/day; for 15 days Experimental Results: Paw withdrawal threshold (PWT) increased Dramatically on postoperative days 11 and 15. |
| References |
|
| Additional Infomation |
Albiflorin is a monoterpene glycoside with formula C23H28O11, originally isolated from the roots of Paeonia lactiflora. It has a role as a plant metabolite and a neuroprotective agent. It is a benzoate ester, a gamma-lactone, a beta-D-glucoside, a monoterpene glycoside, a secondary alcohol and a bridged compound.
Albiflorin has been reported in Paeonia suffruticosa, Paeonia lactiflora, and other organisms with data available. |
| Molecular Formula |
C23H28O11
|
|---|---|
| Molecular Weight |
480.4618
|
| Exact Mass |
480.163
|
| CAS # |
39011-90-0
|
| PubChem CID |
24868421
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
722.1±60.0 °C at 760 mmHg
|
| Flash Point |
248.9±26.4 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.662
|
| LogP |
-0.97
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
830
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@]12C[C@H]([C@@H]3C[C@]1([C@@]3(C(=O)O2)COC(=O)C4=CC=CC=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O
|
| InChi Key |
QQUHMASGPODSIW-ICECTASOSA-N
|
| InChi Code |
InChI=1S/C23H28O11/c1-21-8-13(25)12-7-23(21,33-19-17(28)16(27)15(26)14(9-24)32-19)22(12,20(30)34-21)10-31-18(29)11-5-3-2-4-6-11/h2-6,12-17,19,24-28H,7-10H2,1H3/t12-,13+,14+,15+,16-,17+,19-,21-,22-,23-/m0/s1
|
| Chemical Name |
[(1R,3R,4R,6S,9S)-4-hydroxy-6-methyl-8-oxo-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-oxatricyclo[4.3.0.03,9]nonan-9-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~208.13 mM)
H2O : ~100 mg/mL (~208.13 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (208.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0813 mL | 10.4067 mL | 20.8134 mL | |
| 5 mM | 0.4163 mL | 2.0813 mL | 4.1627 mL | |
| 10 mM | 0.2081 mL | 1.0407 mL | 2.0813 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
